PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop

MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the Vega™ system, the company’s first benchtop long-read sequencing platform. Vega delivers all the functionality of the Revio system, PacBio’s high-throughput long-read sequencer, into a compact, lower-throughput benchtop platform. Offering exceptional data accuracy... Read more

Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024

Basel, 05 November 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December 2024 in San Diego, US. The data underscore Roche’s commitment to advance patient outcomes in... Read more

Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease

New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s disease related amyloid pathology with very good accuracy. In the largest worldwide clinical trial of its kind, the blood-based test showed very good accuracy in ruling out Alzheimer’s pathology in those being investigated for the disease,... Read more

New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer

ItovebiTM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and fulvestrant alone in the INAVO120 study1 The U.S. FDA recently approved the Itovebi-based regimen as a first-line treatment for people with HR-positive, HER2-negative breast cancer with a PIK3CA mutation, one... Read more

Bruker Announces Formation of New Bruker Spatial Biology Division

Bruker Spatial Biology Offers the Widest Range of Industry-leading Multiomic Spatial Biology Platforms to Scientists Globally BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced the formation of a new division, Bruker Spatial Biology, offering the most diverse and comprehensive solutions for spatial biology. Bruker Spatial Biology brings together in operational coordination three entities: the... Read more

PacBio, A*STAR, and Macrogen Unveil State-of-the-Art Lab to Accelerate Genomics Innovation in Singapore

SINGAPORE, Oct. 01, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the Agency for Science, Technology, and Research (A*STAR), and Macrogen, today announced the opening of a state-of-the-art joint laboratory at A*STAR Genome Institute of Singapore (A*STAR GIS) in Singapore. This new facility, located on... Read more

PacBio Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option (the “Option”) covering 100,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 50,000 shares... Read more

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics. Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together... Read more

Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening

Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies. New technology... Read more